Paul C Unangst from 11324 W Monticello Pl, Westchester, IL 60154, age 80, Phone: 7344787954

Us Patents

Aryl Alkenamides Derivatives As Mcp-1 Antagonists
view source
US Patent:

6458806, Oct 1, 2002
Filed:

Aug 12, 1997
Appl. No.:

08/909790
Inventors:

Richard John Booth - Ypsilanti MI
Kenneth Gordon Carson - Needham MA
David Thomas Connor - Ann Arbor MI
Roberta Ellen Glynn - Waltham MA
Bruce David Roth - Plymouth MI
Charles F. Schwender - Glen Gardner NJ
Bharat Kalidas Trivedi - Farmington Hills MI
Paul Charles Unangst - Ann Arbor MI
Assignee:

Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:

A61K 31445
US Classification:

514315, 514327, 514316, 514317, 514318, 514326, 514331, 546184, 546186, 546187, 546192
Abstract:

Aryl alkenamides derivatives of Formula I or a pharmaceutically acceptable salt thereof are novel MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection where V O,S, NH or a bond; Ar can be unsubstituted or substituted benzimidazole, phenyl, biphenyl, pyridyl, naphthyl, quinoline or isoquinoline. The other meanings for the terms are recited in the specification below.

Compounds That Modulate Ppar Activity And Methods For Their Preparation
view source
US Patent:

6875780, Apr 5, 2005
Filed:

Jan 22, 2003
Appl. No.:

10/347749
Inventors:

Bruce J. Auerbach - Ann Arbor MI, US
Larry D. Bratton - Whitmore Lake MI, US
Gary F. Filzen - Ann Arbor MI, US
Andrew G. Geyer - Novi MI, US
Bharat K. Trivedi - Farmington Hills MI, US
Paul C. Unangst - Ann Arbor MI, US
Assignee:

Warner-Lambert Company - Morris Plains NJ
International Classification:

C07D213/02
A61K031/47
US Classification:

514345, 514568, 546301, 562426
Abstract:

This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.

Compounds That Modulate Ppar Activity And Methods For Their Preparation
view source
US Patent:

6939875, Sep 6, 2005
Filed:

Nov 2, 2004
Appl. No.:

10/979617
Inventors:

Bruce J. Auerbach - Ann Arbor MI, US
Larry D. Bratton - Whitmore Lake MI, US
Gary F. Filzen - Ann Arbor MI, US
Andrew G. Geyer - Novi MI, US
Bharat K. Trivedi - Farmington Hills MI, US
Paul C. Unangst - Ann Arbor MI, US
Assignee:

Warner-Lambert Company - Morris Plains NJ
International Classification:

C07D213/02
A61K031/44
US Classification:

514277, 514345, 514568, 546301, 546342, 562426, 562465
Abstract:

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

Compounds That Modulate Ppar Activity And Methods For Their Preparation
view source
US Patent:

6964983, Nov 15, 2005
Filed:

Nov 2, 2004
Appl. No.:

10/979629
Inventors:

Bruce J. Auerbach - Ann Arbor MI, US
Larry D. Bratton - Whitmore Lake MI, US
Gary F. Filzen - Ann Arbor MI, US
Andrew G. Geyer - Novi MI, US
Bharat K. Trivedi - Farmington Hills MI, US
Paul C. Unangst - Ann Arbor MI, US
Assignee:

Warner-Lambert Company, LLC - Morris Plains NJ
International Classification:

A61K031/19
C07C051/00
US Classification:

514568, 562426, 562465
Abstract:

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

Mcp-1 Receptor Antagonists And Methods Of Use Thereof
view source
US Patent:

7067538, Jun 27, 2006
Filed:

May 21, 2003
Appl. No.:

10/442917
Inventors:

Larry D. Bratton - Whitmore Lake MI, US
Alexander J. Bridges - Saline MI, US
David T. Connor - Ann Arbor MI, US
Steven R. Miller - Ann Arbor MI, US
Yuntao Song - Ann Arbor MI, US
Bharat K. Trivedi - Farmington Hills MI, US
Paul C. Unangst - Ann Arbor MI, US
Assignee:

Warner-Lambert Company, LLC - Morris Plains NJ
International Classification:

A01N 43/40
A61K 31/44
US Classification:

514343, 514365, 514372, 514374, 514396, 514709, 5462721, 546339, 548200, 548214, 548215, 5483381, 549 78, 564123, 568 31
Abstract:

The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.

Compounds That Modulate Ppar Activity And Methods Of Preparation
view source
US Patent:

7244763, Jul 17, 2007
Filed:

Feb 6, 2004
Appl. No.:

10/774260
Inventors:

Larry D. Bratton - Whitmore Lake MI, US
Xue-Min Cheng - Ann Arbor MI, US
Noe Erasga - Ann Arbor MI, US
Gary F. Filzen - Ann Arbor MI, US
Andrew G. Geyer - Novi MI, US
Chitase Lee - Ann Arbor MI, US
Bharat K. Trivedi - Farmington Hills MI, US
Paul C. Unangst - Ann Arbor MI, US
Assignee:

Warner Lambert Company LLC - Morris Plains NJ
International Classification:

A61K 31/235
A61K 31/38
A61K 31/35
C07D 405/00
C07D 261/06
US Classification:

514532, 514448, 514443, 514378, 514336, 514456, 560 9, 549 51, 549 70, 549399, 548247, 5462827
Abstract:

This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.

Compounds That Modulate Ppar Activity And Methods For Their Preparation
view source
US Patent:

RE39916, Nov 6, 2007
Filed:

Nov 28, 2005
Appl. No.:

11/288022
Inventors:

Bruce J. Auerbach - Ann Arbor MI, US
Larry D. Bratton - Whitmore Lake MI, US
Gary Filzen - Ann Arbor MI, US
Andrew G. Geyer - Novi MI, US
Bharat K. Trivedi - Farmington Hills MI, US
Paul C. Unangst - Ann Arbor MI, US
Assignee:

Warner Lambert Company - Morris Plains NJ
International Classification:

A61K 31/44
C07D 213/02
US Classification:

514277, 514345, 514568, 546301, 546342, 562426, 562465
Abstract:

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

Chemokine Receptor Antagonists
view source
US Patent:

20020072606, Jun 13, 2002
Filed:

Jul 5, 2001
Appl. No.:

09/900440
Inventors:

Larry Bratton - Whitmore Lake MI, US
Steven Miller - Ann Arbor MI, US
Bruce Roth - Plymouth MI, US
Bharat Trivedi - Ann Arbor MI, US
Paul Unangst - Ann Arbor MI, US
Assignee:

Warner-Lambert Company
International Classification:

C07D471/14
US Classification:

546/050000
Abstract:

The instant invention is a series of compounds which are MCP-1 receptor antagonists of Formula I Also included in the invention are intermediates and processes for the preparation of the compounds as well as methods of using the compounds as agents for the treatment of atherosclerosis, chronic and acute inflammatory disease, chronic and acute immune disorders and transplant rejection as well as for preventing infection by HIV, treating infection by TIV, delaying the onset of AIDS, or treating AIDS.